- Charlotte, North Carolina-based high intensity focused ultrasound (HIFU) technologies specialist SonaCare Medical has reported 5-year outcomes from a multicenter study following focal therapy treatment with its Sonablate
technology of 625 medium to high-risk clinically significant nonmetastatic prostate cancer patients, the company said.
On October 2015, the company received the US FDA clearance for Sonablate
, since then more than 1,200 patients have had a Sonablate
HIFU prostate procedure across the more than 40 locations in the US, including placements at top-tier academic institutions in California, Indiana, Oklahoma, Maryland, New York, Arizona as well as Texas.
Ablation retrospective system Yutkin 19-2 centres Retrospective Sonablate
2014 (5) Ahmed 39-single Prospective Sonablate
2012 (21) centre Udin 84-2 centres Prospective Sonablate
2012 (22) Berge 46-single Prospective Ablatherm 2011 (23) centre Uchida 22-single Prospective Sonablate
2011 (4) centre Zacharakis 31-single Prospective Sonablate
2008 (24) centre Murat 167-single Retrospective Ablatherm 2009 (25) centre Author Median followup PFS rate Focal vs.
Two HIFU technologies, the Ablatherm and the Sonablate
, were available at the moment of treatment of the patient.
This study used the Sonablate
500 (Focus Surgery, Indianapolis, IN, USA) HIFU device.
500, an ultrasound guided system uses a transrectal probe to carry out prostate cancer focal ablation .
The developer of ultrasonic medical device technology for the treatment of cancer and other chronic health conditions said it has introduced its Sonablate
500 for prostate cancer into the European market.
Misonix develops, manufactures, and markets medical, scientific and industrial ultrasonic and air pollution systems and maintains a minority equity position in Focus Surgery as its exclusive manufacturer of the Sonablate
-- Focus Surgery entered into an exclusive International Distribution Agreement, outside of Asia and the United States, with Endocare Corporation for its Sonablate
500 unit, which treats prostate cancer and Benign Prostatic Hyperplasia (BPH) using High Intensity Focused Ultrasound, (HIFU).
HIFU treatment was performed using the Sonablate
500 machine (SonaCare Medical, Charlotte, NC).
- The FDA has approved for market in the United States the Sonablate
for the ablation of prostate tissue and the treatment is now available in the US, US-based prostate cancer treatment provider HIFU Prostate Services said.
Five years experience of transrectal high-intensity focused ultrasound using the Sonablate
device in the treatment of localized prostate cancer.